Considering the growing interest in pharmacologically targeting YAP/TAZ to eradicate a variety of solid tumors, Yap/Taz dispensability in haematopoiesis has direct implications on the safety of such approach in terms of unwanted side effects, potentially detrimental for systemic haematopoiesis, which are frequently associated with cancer treatments. Here, YAP1 is linked to cancer.